Reference : Preoperative hyperfractionated accelerated radiotherapy (HART) in locally advanced recta...
Scientific journals : Article
Human health sciences : Oncology
http://hdl.handle.net/2268/30930
Preoperative hyperfractionated accelerated radiotherapy (HART) in locally advanced rectal cancer (LARC) immediately followed by surgery. A prospective phase II trial
English
Coucke, Philippe mailto [Hôpital Maisonneuve-Rosemont, Montreal > Radiation-Oncology > > >]
Notter [> >]
Stamm [Kantonspital Aarau, Aarau > > > >]
Stamm [Kantonspital Aarau, Aarau > > > >]
Matter [> >]
Fasolini [Kantonspital Aarau, Aarau > > > >]
Schlumpf [Kantonspital Aarau, Aarau > > > >]
Matzinger [Centre Hospitalier Universitaire Vaudois > > > >]
bouzourene [ > > ]
Jun-2005
Radiotherapy & Oncology
Elsevier Scientific
Yes (verified by ORBi)
International
0167-8140
Limerick
Ireland
[en] Background and purpose

We aim to report on local control in a phase II trial on preoperative hyperfractionated and accelerated radiotherapy schedule (HART) in locally advanced resectable rectal cancer (LARC). This fractionation schedule was designed to keep the overall treatment time (OTT) as short as possible.
Patients and methods

This is a prospective trial on patients with UICC stages II and III rectal cancer. The patients were submitted to a total dose of 41.6 Gy, delivered in 2.5 weeks at 1.6 Gy per fraction twice a day with a 6-h interfraction interval. Surgery was performed within 1 week after the end of irradiation. Adjuvant chemotherapy was delivered in a subset of patients.
Results

Two hundred and seventy nine patients were entered and 250 are fully assessable, with a median follow-up of 39 months. The 5-years actuarial local control (LC) rate is 91.7%. The overall survival (OS) is 59.6%. The freedom from disease relapse (FDR) is 71.5%. Downstaging was observed in 38% of the tumors.
Conclusion

The actuarial LC at 5 years is 91.7%, although we are dealing with stages II–III LARC, mainly located in the lower rectum (median distance=5 cm). The pattern of failure is dominated by distant metastases and treatment intensification will obviously require a systemic approach.
Researchers ; Professionals ; Students ; General public ; Others
http://hdl.handle.net/2268/30930

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
PHASE II Trial~1.pdfPublisher postprint84.12 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.